Why it matters:
Aliskiren is a direct renin inhibitor; renin converts angiotensinogen to angiotensin. It is indicated for essential hypertension either alone or in combination with other antihypertensives. The patent expired April 2020 but no generics are available yet.
NICE states there is insufficient evidence of its effectiveness to determine its suitability for use in resistant hypertension.
While aliskiren has shown comparable efficacy to other antihypertensive agents in terms of blood pressure reduction, its effects on mortality and long-term morbidity are currently unknown.NHS England recommend that GPs:
Description: Cost of Aliskiren per 1000 patients
Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.